Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3736-3745

  Kumar, S Ram ^a,d   Scehnet, Jeffrey S ^a   Ley, Eric J ^a   Singh, Jasbir ^a   Krasnoperov, Valery ^e   Liu, Ren ^a   Manchanda, Parmeet K ^a   Ladner, Robert D ^a   Hawes, Debra ^a   Weaver, Fred A ^a   Beart, Robert W ^a   Singh, Gagandeep ^a   Nguyen, Cu ^d   Kahn, Michael ^b,c,d   Gill, Parkash S ^a,e  

^a Department of Pathology ^*  (United States)

^b Keck School of Medicine   (United States)

^c University of Maryland Shady Grove Campus   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Vasgene Thereapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY MECHANISM; STEM CELL;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; HT29 CELLS; HUMANS; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; RECEPTOR, EPHB2; RECEPTOR, EPHB4; RNA, SMALL INTERFERING; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 65949098678     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3232     Document Type: Article

References (25)

1. Augustin HG, Reiss Y. EphB receptors and ephrin Bligands:regulators of vascular assembly and homeostasis. Cell Tissue Res 2003;314:25-31.
2. Arvanitis D, Davy A. Eph/ephrin signaling:networks. Genes Dev 2008;22:416-29.
3. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008;133:38-52.
4. Gale NW, BalukP, Pan L, et al. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 2003;230:151-60.
5. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998;93:741-53.
6. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin- B2 in cardiovascular development. Mol Cell 1999;4:403-14.
7. Batlle E, Henderson JT, Beghtel H, et al. β-Catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrin B. Cell 2002;111:251-63.
8. Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/β-cateninmediated survivin gene expression. Oncogene 2005;24:3619-31.
9. McMillan M, Kahn M. Investigating Wnt signaling:a chemogenomic safari. Drug Discov Today 2005;10:1467-74.
10. van de Wetering M, Sancho E, Verweij C, et al. The β- catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-50.
11. Polakis P. The oncogenic activation of β-catenin. Curr Opin Genet Dev 1999;9:15-21.
12. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997;1332:F127-47.
13. Batlle E, Bacani J, Begthel H, et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005;435:1126-30.
14. Guo DL, Zhang J, Yuen ST, et al. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 2006;27:454-64.
15. Jubb AM, Zhong F, Bheddah S, et al. EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res 2005;11:5181-7.
16. Liu W, Ahmad SA, Jung YD, et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002;94:934-9.
17. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2001;2:15.
18. Davalos V, Dopeso H, Castano J, et al. EPHB4 and survival of colorectal cancer patients. Cancer Res 2006;66:8943-8.
19. Kumar SR, Singh J, Xia G, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006;169:279-93.
20. Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005;37:1289-95.
21. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription. Proc Natl Acad Sci U S A 2004;101:12682-7.
22. Teo JL, Ma H, Nguyen C, Lam C, Kahn M. Specific inhibition of CBP/β-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc Natl Acad Sci U S A 2005;102:12171-6.
23. Miyabayashi T, Teo JL, Yamamoto M, McMillan M, Nguyen C, Kahn M. Wnt/β-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci U S A 2007;104:5668-73.
24. Munarini N, Jager R, Abderhalden S, et al. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J Cell Sci 2002;115:25-37.
25. Adams RH, Wilkinson GA, Weiss C, et al. Roles of ephrin Bligands and EphB receptors in cardiovascular development:demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999;13:295-306.